https://www.nrgtherapeutics.com/wp-content/uploads/2026/08/Longevity-News-image.jpg8191238Webadmhttps://www.nrgtherapeutics.com/wp-content/uploads/2026/07/NRG_Logo.pngWebadm2025-10-09 08:00:562026-08-14 13:17:25Is this mitochondria’s big moment?
https://www.nrgtherapeutics.com/wp-content/uploads/2026/08/BIA-banner.jpg8191238Webadmhttps://www.nrgtherapeutics.com/wp-content/uploads/2026/07/NRG_Logo.pngWebadm2025-10-08 08:00:342026-08-14 13:18:35Biotechs, BIA, patient charities and investors: the power of relationships
https://www.nrgtherapeutics.com/wp-content/uploads/2026/08/NRG-emerging-company-profile-1-oct25.jpg10001500Webadmhttps://www.nrgtherapeutics.com/wp-content/uploads/2026/07/NRG_Logo.pngWebadm2025-10-01 08:00:162026-09-09 17:38:56NRG Therapeutics: Restoring motor neuron function via mitochondria
https://www.nrgtherapeutics.com/wp-content/uploads/2026/08/NRG-Therapeutics-ounding-team-in-lab.jpg10001500Webadmhttps://www.nrgtherapeutics.com/wp-content/uploads/2026/07/NRG_Logo.pngWebadm2025-09-08 08:05:422026-09-09 17:39:46NRG raises $67M to test mitochondrial pore inhibitor in ALS
https://www.nrgtherapeutics.com/wp-content/uploads/2026/08/Neil_Miller_CEO_NRG_Therapeutics_-_in_lab.webp9001600Webadmhttps://www.nrgtherapeutics.com/wp-content/uploads/2026/07/NRG_Logo.pngWebadm2025-09-08 08:04:132026-08-14 13:52:49A UK biotech takes aim at Parkinson’s, ALS by drugging mitochondria
https://www.nrgtherapeutics.com/wp-content/uploads/2026/08/AXKEEI4DDZEXNHXPEMIEQBLT54_2.jpg8441500Webadmhttps://www.nrgtherapeutics.com/wp-content/uploads/2026/07/NRG_Logo.pngWebadm2025-09-08 08:03:052026-09-09 17:40:02UK’s NRG Powers Up With £50m For Promising Mitochondrial Therapy
https://www.nrgtherapeutics.com/wp-content/uploads/2026/08/NRG-raises-GBP-50-M-EMBARGO-MON-3AM-ET-164529.webp8001200Webadmhttps://www.nrgtherapeutics.com/wp-content/uploads/2026/07/NRG_Logo.pngWebadm2025-09-08 08:02:412026-08-14 13:56:34NRG raises $67 million for a small molecule for Parkinson’s and ALS
https://www.nrgtherapeutics.com/wp-content/uploads/2026/08/Biotech-TV.jpg532959Webadmhttps://www.nrgtherapeutics.com/wp-content/uploads/2026/07/NRG_Logo.pngWebadm2025-09-08 08:01:482026-09-10 10:24:24Stevenage, UK based NRG Therapeutics raised a $67M series B today to advance its aim to restore mitochondrial function and slow the progression of neurodegenerative diseases like Parkinson’s and ALS
https://www.nrgtherapeutics.com/wp-content/uploads/2026/08/Neil_Miller_CEO_NRG_Therapeutics_-_in_lab.webp9001600Webadmhttps://www.nrgtherapeutics.com/wp-content/uploads/2026/07/NRG_Logo.pngWebadm2025-09-08 08:00:342026-08-14 14:16:22A British mitochondrial startup wants to break ground in ALS and Parkinson’s. It has £50M to try
https://www.nrgtherapeutics.com/wp-content/uploads/2026/08/movers-shakers.jpg8191238Webadmhttps://www.nrgtherapeutics.com/wp-content/uploads/2026/07/NRG_Logo.pngWebadm2025-03-08 08:00:022026-09-10 10:24:02Mitochondria: Movers and Shakers – a podcast about life with Parkinson’s
https://www.nrgtherapeutics.com/wp-content/uploads/2026/08/BusinessWeekly_NRG.jpg8191238Webadmhttps://www.nrgtherapeutics.com/wp-content/uploads/2026/07/NRG_Logo.pngWebadm2024-10-31 08:00:162026-08-14 14:24:06NRG Therapeutics launches Series B after $5m boost from Michael J. Fox Foundation
Is this mitochondria’s big moment?
Longevity Technology
Read more
Biotechs, BIA, patient charities and investors: the power of relationships
BIA, UK BioIndustry Association
Read more
NRG Therapeutics: Restoring motor neuron function via mitochondria
BioCentury
Read more
(behind a paywall)
NRG raises $67M to test mitochondrial pore inhibitor in ALS
BioWorld
Read more
(behind a paywall)
A UK biotech takes aim at Parkinson’s, ALS by drugging mitochondria
Biopharma Dive
Read more
UK’s NRG Powers Up With £50m For Promising Mitochondrial Therapy
SCRIP
Read more
(behind a paywall)
NRG raises $67 million for a small molecule for Parkinson’s and ALS
c&en
Read more
Stevenage, UK based NRG Therapeutics raised a $67M series B today to advance its aim to restore mitochondrial function and slow the progression of neurodegenerative diseases like Parkinson’s and ALS
Biotech TV
Watch more
A British mitochondrial startup wants to break ground in ALS and Parkinson’s. It has £50M to try
Endpoints News
Read more
Mitochondria: Movers and Shakers – a podcast about life with Parkinson’s
Apple Podcasts
Listen more
Novel Parkinson’s therapy protects mitochondrial function
Drug Discovery World
Read more
NRG Therapeutics launches Series B after $5m boost from Michael J. Fox Foundation
Business Weekly
Read more